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Abstract Studies have demonstrated suboptimal treatmentof acute severe asthma and chronicobstructive pulmon-
ary disease COPD).We examined the quality of treatment in Denmark and the effect of intervention, by publication of
recommendations for standardised treatment. All 70 hospitals in Denmark with emergency facilities participated in a
telephone questionnaire, examining treatmentbehaviours amonghouse officers.The surveywasrepeated 3 years later,
after publication of national recommendations for treatment of acute exacerbations of asthma and COPD. The
response rate in both surveys was 100%. An insufficient handling of nebulisers, a huge variation in the delivered dose
of bronchodilators and a suboptimal use of corticosteroids was found. A significant trend towards more liberate use
of oxygen was seen in both asthma (3.2 lmin1 versus 4.8 lmin1, Po0.001) and COPD (1.5 lmin1 versus 1.9 lmin1,
P = 0.047). Further, a huge difference in treatment behaviours was revealed from this survey.The knowledge among
house officers of basic principles of treatment was insufficient.Treatment behaviour was only moderately affected by
national publication of detailed recommendations for treatment.This study indicates a need for implementing tools for
qualitycontrol.r2002 Elsevier Science Ltd.Allrights reserved.
doi:10.1053/rmed.2002.1331, available online at http://www.idealibrary.comon
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Studies from several countries have demonstrated
suboptimal treatment of acute asthma and chronic
obstructive pulmonary disease (COPD) (1^3), but no
studies have evaluated the quality of treatment in Den-
mark and examined if intervention by dissemination of
guidelines for standardised treatment can improve the
quality.
We performed a study to evaluate the treatment
strategy and knowledge among Danish house o⁄cers
working in the emergency setting and thus engagedwith
the initial treatmentof patientswith acute exacerbations
of asthma andCOPD.The ¢ndingswere compared to re-
commendations from commonly used guidelines (4^10)
in order to evaluate the actual treatment and to clarifyReceived 24 September 2001, accepted in revised form 6March 2002.
Correspondence should be addressed to: Klaus Phanareth,MD, PhD,
SnogegCrdsvej 99, 2820 Gentofte,Denmark.
Email: phanareth@dadlnet.dkif standardisation and improvement is needed. Based on
the fact that some procedures are carried out by the
nursing sta¡,we expanded the survey to include answers
from a selected group of senior nurses working with
acute asthma and COPD.
Three years later a follow-up study was performed in
order to investigate if a change in treatment behaviour
had occurred, as speci¢c interventions in the meantime
had been performedwith a potential of modifying treat-
ment.The same questionnaire was used in the follow-up
study and the results were compared.
METHODS
A telephone survey including all 70 Danish hospitals with
emergency departments was performed during the
months April through May 1996.We phoned the house
o⁄cers in charge in the emergency department or in
the acute setting with the potential of receiving patients
with acute exacerbations of asthma and COPD.Weused
654 RESPIRATORYMEDICINEa standardardised questionnaire (Table 1) on nebuliser
therapy, choice and dosage of inhaled bronchodilators,
oxygen therapy, intravenous bronchodilators, and corti-
costeroid treatment.When relevant, the questionswere
asked separately for asthma and COPD. It was made
clear to the house o⁄cer on call that the questions con-
cerned the initial treatment within the ¢rst few hours
upon arrival of a patient with a severe exacerbation in
asthma or COPD.
Telephone interview lasted around 30min and was
performed in hours known not to be so busy.The tele-
phone survey was chosen instead of a written question-
naire in order to receive unprepared answers and to
optimise the response rate. In Danish hospitals, it is
usually the nursing sta¡ who are responsible for the
handling of nebuliser therapy whereas the physician, as
a minimum, prescribe the medication inhaled. Conse-
quently, a minor telephone survey among the nursing
sta¡ was established, including 14 hospitals where ques-
tions concerning the handling of nebuliser therapy were
asked.
The results from the initial survey were published in
1997 in the weekly bulletin for Danish physicians, along
with a recommendation for the treatment of acute se-
vere asthma andCOPD (11).Thekeyelementwas a treat-
ment algorithm with speci¢c recommendations for
nebuliser handling, oxygen therapy, inhaled bronchodila-
tors, and corticosteroid therapy. Intravenous bronchodi-
lators were not recommended. The Danish Society of
Respiratory Medicine also in 1997 published a guideline
on the treatment of COPD (10), providing further focus
on the treatment of acute exacerbations.The above na-
tionwide distributed publications were considered as an
intervention with the possibility of modifying treatment
behaviours and subsequently we examined if this had oc-
curred.
The follow-up study was performed in1999 fromMay
to June and included all hospitals participating in the ¢rst
survey.The same questionnairewasused inboth surveys.
All interviewers (four persons) were trained in asking
questions and perceiving answers, in order to minimise
inter-personal variation.
Statistics
The answers from the two surveys (1996 and1999) were
categorised and coded to allow statistic calculations. Dif-
ferences between surveys were compared with a two-
sided chi-square test (frequency distributions) or an in-
dependent samples t-test (continuous variables). In com-
parisons of asthma and COPD within the same survey, a
two-sided chi-square test or a paired samples t-test was
used. In all tests, a P-value of less than 0.05 was consid-
ered as signi¢cant.RESULTS
The response rate was 100% in both surveys and all 70
doctors completed the questionnaire. None of the phy-
sicians asked had participated in the initial survey from
1996.Detailed distribution of answers is shown inTable1.
Nebuliser therapy
All hospitals used nebulisers for the delivery of inhaled
medication. Physicians were asked about speci¢cations
of the nebuliser system used. There was no signi¢cant
change in knowledge of the speci¢cations from 1996 to
1999 (data not shown).
Abouthalf of the house o⁄cers suggested oxygen as a
propellant gas for nebuliser therapy and the rest used
ambient air, a combination of both or did not knowwhat
to use.Therewas no signi¢cant di¡erence between asth-
ma and COPD and no change from1996 to 1999, except
for a signi¢cant increase in the use of oxygen/ambient air
combination for both asthma (1% vs 13%, P = 0.006) and
COPD (3 vs13%, P = 0.03).
Only one-third of the physicians prescribed an ade-
quate £ow (6^8 l) for the nebuliser in both surveys.The
remaining suggested inadequate £ow (too low or too
high) or did not know which £ow to use. There was no
signi¢cant change from1996 to1999.
One-third of the physicians prescribed nebuliser ther-
apy ‘‘as needed’’whereasmore than half used ¢xed inter-
vals. There was a signi¢cant increase in the number of
physicians whowere not aware of the recommended ¢ll
volume for the nebuliser from1996 to1999 (54 vs 73%, P
= 0.02).
When repeating the questions on nebuliser therapy
among a group of senior emergency room nurses, we
also found divergent answers in-between the group and
compared to the physicians. Seventy-¢ve percent of the
nurses used air as a driving gas in contrast to the physi-
cianswheremore than half prescribed oxygen.Only 30%
of the nurses applied an appropriate £ow for the nebuli-
ser.
Inhaled bronchodilators
About two-thirds of the physicians would prescribe a
combination therapy with inhaled beta2-agonist and
ipratropium bromide, whereas one-third used mono
therapy with a beta2-agonist, showing no signi¢cant
change over time. Dosage of ipratropium bromide re-
mained also unchanged from 1996 to 1999, whereas the
mean nominal dose of beta2-agonistwas signi¢cantly re-
duced in the same period (3.1vs 2.6mg, P = 0.019).
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TREATMENTOFACUTE,SEVEREASTHMA ANDCOPD 655Oxygen therapy
Allphysiciansprescribed a nasalpronge for initial oxygen
delivery, either single or double channel. None sug-
gested the use of aVenturimask.
Physicians in both surveys prescribed signi¢cantly
more oxygen for the asthma patient compared to the
COPD patient. A signi¢cant trend towards more liber-
ate administration of oxygenwas seen in both groups in
the follow-up study.Themeanoxygen£owused for asth-
ma patients increased from 3.2 lmin1 in 1996 to
4.8 lmin1in1999 (P = 0.001). In COPD, themean oxygen
£owrose from1.5 lmin1in1996 to1.9 lmin1in1999 (P =
0.047) (Fig.1).
Corticosteroids
In both surveys, about 75% of the physicians would rou-
tinely use systemic corticosteroids with no signi¢cant
change over time and the mean dose of corticosteroids
was also unchanged from 1996 to 1999. However, fewer
physicians prescribedvery small doses of corticosteroids
in1999 compared to1996 (4 vs15%, P = 0.03).
Other treatments
The frequency of prescribing intravenous beta2-agonist,
either as a bolus or as an infusion, was signi¢cantly
reduced from 1996 to 1999. An intravenous bolus was
used routinely by 44% in1996 vs 19% in1999 (P = 0.002).
Intravenous infusionwasusedroutinelyby 77% in1996 vs
50% in1999 (P = 0.001).
The use of methylxanthines was found to be un-
changed comparing the two surveys with only the
minority of the physicians routinely using this drug
(5 vs 4%,NS).
DISCUSSION
This study shows that knowledge about the initial treat-
ment of severe exacerbations in asthma and COPD is in-
su⁄cient among junior house o⁄cers engaged in this
¢eld.Whereas nebuliser treatmentwithbronchodilators
is a well-established ¢rst-line of treatment, the knowl-
edge of the principles and the handling of the nebuliser
is very super¢cial, as is the case among emergency room
nurses handling this therapy. In general, the knowledge
of corticosteroid therapy, oxygen therapy, and intrave-
nousbronchodilators ismore adequate.However, a large
variation exists, constituting a possibility of inadequate
medical therapy for several patients. Judged by the re-
ceived answers, it is inevitable that in some situations,
patients will receive too little oxygen and insu⁄cient
doses of beta2-agonist corticosteroids. Intravenous
bronchodilators probably used are more than appropri-
ate, which canbe regarded as a minor problem, yetwith
the possibility of unnecessary side-e¡ects.
656 RESPIRATORYMEDICINEWe found very few signi¢cant changes in treatment
habits comparing 1996 and 1999, despite the dissemina-
tion of national recommendations on this issue in-be-
tween the two surveys. The recommendations were
accompanied by a number of informal initiatives, such as
pregraduate teaching and a series of departmental lec-
tures for junior doctors and medical students by some
of the authors. The follow-up survey showed some im-
provement regarding oxygen therapy, minor improve-
ments on corticosteroid therapy and a less common use
of intravenous bronchodilators. The changes were in
agreementwith the focus of the publishedrecommenda-
tions based on the ¢rst survey (11), but it is important to
emphasise that treatment behaviour only improved
slightly.
The treatment behaviour of physicians is determined
by numerous factors such as national recommendations,
scienti¢c papers, text books, health information on the
Internet, conferences, lectures, departmental instruc-
tions, and the learning from senior colleagues. We do
notknow, however, the relative importance of these fac-
tors, which, among others, will depend on the level of
experience for the individual doctor. In this survey, we
only examined the possible in£uence of nation-wide dis-
tributed and detailed recommendations. This ‘‘interven-
tion’’ is not in any way controlled, as we, in this study-
design, have no possibility to control for trends in treat-
ment behaviour caused by some of the other factors.
We used the telephone interview in order to get un-
biased information from the medical o⁄cers in charge
and responsible for the actual treatment and care ofFIG. 1. Prescriptionofoxygenin acute exacerbationsof asthma
andCOPDcomparing1996 and1999.The distributionof answers
inpercent in each ofthe categories is shown.patients admitted with acute asthma and COPD. If we
had chosen the written interview, we would de¢nitely
have had a lower response rate and furthermore the de-
partments would have had time to adjust their answers
according to the guidelines, possibly making results less
valuable. It was speci¢ed that the questions concerned
only the management of patients with acute severe ex-
acerbations, which in fact can be perceived quite di¡er-
ently. This may have induced a larger variation in the
answers than would have been the case if all doctors
were treating the same patient. However, the variation
in answers to the question of driving gas £ow, which is
not related to the severity of the disease, was even as
large indicating that the found variationwas real.
The comparisonsbetween the initial study and the fol-
low-up study wouldhavebeen statistically stronger if we
had been able to interview the same physician on both
occasions. However, this is not feasible among junior
doctors andwebelieve that the individual treatment be-
haviours to some degree must re£ect the ‘‘internal con-
sensus’’ in a department, allowing us to detect a possible
change in treatment strategies.
Nebulisers
The exclusive use of nebulisers in Denmark is more
based on tradition than on evidence. In a recently pub-
lishedCochranereviewbyCatesetal., themetered-dose
inhaler with a holding chamber proved at least equiva-
lent to the nebuliser (12). Other studies have indicated
the use of a dry powder inhaler as an option in the acute
setting (13^15).
When comparing the recommendation from the evi-
dence-based BTS guidelines on nebuliser therapy (16)
with the answers from the Danish physicians, we found
that the knowledge and handling of nebuliser systems
was inadequateFwith no major di¡erences comparing
the two surveys.
BTS guidelineshavepointedout several factors, essen-
tial in providing optimal performance of the nebuliser,
i.e. the driving gas £ow rate and the ¢ll volume Only
one-third of the doctors would prescribe an optimal
£ow and more than half did not know which ¢ll volume
to use. In general, none was aware of the importance of
these parameters in any of the surveys.
The administration of life-savingmedication by nebuli-
sers demands a correct handling and a misuse of the de-
vice by not adhering to speci¢c recommendations from
the manufacturers can have a great impact on the per-
formance of the nebuliser resulting in insu⁄cient appli-
cation of inhaled drug to the patient (17,18).We believe
that emergency equipment should be standardized and
accompanied by simple and clear instructions and the
emergency sta¡ should receive frequent education,
aimed towards on optimal e⁄cacy of the devices.
TREATMENTOFACUTE,SEVEREASTHMA ANDCOPD 657Inhaled bronchodilators
It was generally agreed among the doctors that inhala-
tion therapy with beta-agonists was the ¢rst choice in
both asthma and COPDFwhich is in agreement with
the commonly used guidelines (4^6;8^10). More than
60% of all doctors prescribed combination therapy with
a beta2-agonist and ipratropium bromide according to
the guidelines (4,5,8^10). However, the majority of the
doctors were not aware of this because they used Bero-
duals (a ¢xed combination of fenoterol and ipratropium
bromide) and could not account for the generics when
asked.
When adjusting for the relative potency of the di¡er-
ent beta2-agonists, we found a di¡erence of a factor
of 4 between the nominal doses used inDanish hospitals.
When combining this with the di¡erence in nebuliser
performance between di¡erent brands of nebuli-
sersFwhich is a factor of 3.5 according to a study by
Lo¡ert et al. (19)Fa consequence could be a di¡erence
of a factor of 14 in the delivered dose of beta2-agonist.
Such a di¡erence was actually demonstrated in our
study.
The mean nominal dose of beta2^agonist decreased
signi¢cantly by 0.5mg comparing the two surveys and
we have no obvious explanation for this.
Nebuliser treatment with inhaled bronchodilators is
well established in Danish hospital units. However, the
knowledge on potency, dosage, and frequency of inhaled
bronchodilators is sparse and has not increased during a
3-year period. There is a need for standardised treat-
ment procedures in the usage of bronchodilators, secur-
ing the patient an acceptable dose of a maybe life-saving
drug. The di¡erence in dosages revealed in this study is
not acceptable.
Oxygen therapy
The administration of oxygen is one of the key elements
in the management of acute severe exacerbations
of asthma and COPD (4^7,9,10). All severely obstructed
patients are hypoxemic and require oxygen. Studies
in COPD have shown that hypercapnia induced by
oxygen administration can be reverted in a few
minutes by a gradual reduction in oxygen delivery (20)
and that respiratory acidosis is infrequent in severely
obstructed patients treated with liberal doses of
oxygen, aiming at an oxygen-saturation above
90% (21).
Trends in the administration of oxygen therapy have
changed comparing the two surveys. The mean dose
(£ow) of oxygen delivered between inhalations has in-
creased 25% in asthma (P40.005) and 17% in COPD (P
= 0.047). In general, Danish physicians seem to have
reached the recommended level of oxygen administra-
tion in both asthma (4,5) and COPD (8,10).Corticosteroids
The e¡ect of the administration of corticosteroids in
acute exacerbations of asthma and COPD is well docu-
mented (22^25).There is no evidence to support a clini-
cal relevant di¡erence in treatment e¡ect between
intravenous and oral administration of corticosteroids
in asthma, as long as the dose is kept above 30mgof pre-
dnisolone or equivalent in the ¢rst 24h (22). In COPD,
the issue of the route of administration to our knowl-
edge has not been investigated, but some information
on the initial dosing is available, indicating 125mg of
methyl-prednisolone to be an option (25).O⁄cial guide-
lines are not speci¢c on this matter neither in asthma
nor in COPD (4,5,7,8,10).
We were not able to detect any major di¡erences
when comparing the use of corticosteroids between
1996 and1999. About 75% of the doctors in both surveys
wouldroutinelyuse this strategy and themajority would
prescribe between 30 and 100mg of prednisolone. It is
not acceptable that one of the four physicians do not in-
itiate corticosteroid therapy at a severe exacerbation of
asthma or COPD, and dissemination of detailed instruc-
tions on this issue have had no obvious e¡ect on the
treatment behaviours.
Intravenous bronchodilators
We found a signi¢cant reduction in the regular usage of
intravenous beta2-agonists from1996 to1999.This trend
is well in line with several studies on asthma patients,
showing the inhaled route to be superior or at least
equivalent to the intravenous route (26) though several
o⁄cial guidelines still approve the latter strategy (5,6).
The issue has not been formally investigated in COPD
and the o⁄cial guidelines are diverging in their recom-
mendations (7,10).
The use of methylxanthines in the treatment of acute
exacerbation is no longer a routine optionveri¢edby the
answers from the vastmajority of physicians in both sur-
veys. The evidence to support this is strong in asthma
(27) but weak in COPDF the latter re£ected in di¡er-
ent recommendations from o⁄cial guidelines (7,9,10).
CONCLUSION
A noticeable variation in treatment procedures related
to acute exacerbations of asthma and COPD was found
in this study.The knowledge among house o⁄cers of ba-
sic principles of treatment was insu⁄cient. Treatment
behavior was only moderately a¡ected by national pub-
lication of detailed recommendations for treatment.The
new generation of clinical guidelines should be based
upon detailed practical issues from the clinical situation
taking the principles of evidence-basedmedicine into ac-
count.
658 RESPIRATORYMEDICINEDespite the uncontrolled design of this study, it also
demonstrates the need for implementing instruments of
quality control.
We have proposed a clinical evidence-based guideline
using the knowledge gathered from this study aimed to-
wards the practical clinical situation when treating pa-
tients with acute severe asthma and COPD.
The guideline is published in this issue of Respiratory
Medicine.
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